A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial
Autoři:
Mhairi Maskew aff001; Alana T. Brennan aff001; Matthew P. Fox aff001; Lungisile Vezi aff001; Willem D. F. Venter aff004; Peter Ehrenkranz aff005; Sydney Rosen aff001
Působiště autorů:
Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
aff001; Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America
aff002; Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America
aff003; Ezintsha, Wits Reproductive Health and HIV Institute, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
aff004; Bill & Melinda Gates Foundation, Seattle, Washington, United States of America
aff005
Vyšlo v časopise:
A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial. PLoS Med 17(8): e1003226. doi:10.1371/journal.pmed.1003226
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pmed.1003226
Souhrn
Background
Many countries encourage same-day initiation of antiretroviral therapy (ART), but evidence on eligibility for same-day initiation, how best to implement it, and its impact on outcomes remains scarce. Building on the Simplified Algorithm for Treatment Eligibility (SLATE) I trial, in which nearly half of participants were ineligible for same-day initiation mainly because of TB symptoms, the study evaluated the revised SLATE II algorithm, which allowed same-day initiation for patients with mild TB symptoms and other less serious reasons for delay.
Methods and findings
SLATE II was a nonblinded, 1:1 individually randomized pragmatic trial at three primary healthcare clinics in Johannesburg, South Africa. It randomized adult patients presenting for an HIV test or any HIV care but not yet on ART. Intervention arm patients were assessed with a symptom screen, medical history, brief physical examination, and readiness questionnaire to distinguish between patients eligible for immediate ART dispensing and those requiring further care before initiation. Standard arm patients received usual care. Follow-up was by review of routine clinic records. Primary outcomes were (1) ART initiation in ≤7 days and (2) ART initiation in ≤28 days and retention in care at 8 months (composite outcome). From 14 March to 18 September 2018, 593 adult HIV+, nonpregnant patients were enrolled (median interquartile range [IQR] age 35 [29–43]; 63% (n = 373) female; median CD4 count 293 [133–487]). Half of study patients (n = 295) presented with TB symptoms, whereas only 13 (4%) standard arm and 7 (2%) intervention arm patients tested positive for TB disease. Among 140 intervention arm patients with TB symptoms, 72% were eligible for same-day initiation. Initiation was higher in the intervention (n = 296) versus standard arm (n = 297) by 7 days (91% versus 68%; risk difference [RD] 23% [95% confidence interval (CI) 17%–29%]) and 28 days (94% versus 82%; RD 12% [7%–17%]) after enrollment. In total, 87% of intervention and 38% of standard arm patients initiated on the same day. By 8 months after study enrollment, 74% (220/296) of intervention and 59% (175/297) of standard arm patients had both initiated ART in ≤28 days and been retained in care (RD 15% [7%–23%]). Among the 41% of participants with viral load results available, suppression was 90% in the standard arm and 92% in the intervention arm among patients initiated in ≤28 days. No ART-associated adverse events were reported after initiation; two intervention and four standard arm patients were reported to have died during passive follow-up. Limitations of the study included limited geographic generalizability, exclusion of patients too sick to consent, fluctuations in procedures in the standard arm over the course of the study, high fidelity to the trial protocol by study staff, and the possibility of overestimating loss to follow-up due to data constraints.
Conclusions
More than 85% of patients presenting for HIV testing or care, including those newly diagnosed, were eligible and ready for same-day initiation under the SLATE II algorithm. The algorithm increased initiation within 7 days without appearing to compromise retention and viral suppression at 8 months, offering a practical and acceptable approach that can be widely and immediately utilized by existing providers.
Trial registration
Clinicaltrials.gov NCT03315013, registered 19 October 2017. First participant enrolled 14 March 2018.
Klíčová slova:
Algorithms – Antiretroviral therapy – HIV – HIV diagnosis and management – South Africa – Tuberculosis – Viral load – Virus testing
Zdroje
1. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017 [cited 2020 Jun 9]. Available from: https://www.who.int/hiv/pub/guidelines/advanced-HIV-disease/en/.
2. Rosen S, Fox MP, Larson B, Sow PS, Ehrenkranz PD, Venter F, et al. Accelerating the uptake and timing of antiretroviral therapy initiation in sub-Saharan Africa: an operations research agenda. PLoS Med. 2016;13: e1002106. doi: 10.1371/journal.pmed.1002106 27505444
3. Ahmed S, Autrey J, Katz IT, Fox MP, Rosen S, Onoya D, et al. Why do people living with HIV not initiate treatment? A systematic review of qualitative evidence from low- and middle-income countries. Soc Sci Med. 2018;213: 72–84. doi: 10.1016/j.socscimed.2018.05.048 30059900
4. Fox MP, Rosen S, Geldsetzer P, Barnighausen T, Negussie E, Beanland R. Interventions to improve the rate or timing of initiation of antiretroviral therapy for HIV in sub-Saharan Africa: Meta-analyses of effectiveness. J Int AIDS Soc. 2016; 19:20888. doi: 10.7448/IAS.19.1.20888 27507249
5. Hoenigl M, Chaillon A, Moore DJ, Morris SR, Mehta SR, Gianella S, et al. Rapid HIV viral load suppression in those initiating antiretroviral therapy at first visit after HIV diagnosis. Sci Rep. 2016;6: 1–5. doi: 10.1038/s41598-016-0001-8
6. Seekaew P. Same-day antiretroviral therapy initiation in Thailand: Different models and initial outcomes from scale-up in 6 provinces in Thailand. Abstract WEAB0102, 10th IAS Conference on HIV Science; 2019 Ju 21–24, Mexico City.
7. Koenig SP, Dorvil N, De JG, Riviere C, Faustin M, Lavoile K, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med. 2017;14: e1002357. doi: 10.1371/journal.pmed.1002357 28742880
8. Amanyire G, Semitala FC, Namusobya J, Katuramu R, Kampiire L, Wallenta J, et al. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV. 2016; 3:e539–e548. doi: 10.1016/S2352-3018(16)30090-X 27658873
9. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med. 2016;13: e1002015. doi: 10.1371/journal.pmed.1002015 27163694
10. Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A, et al. Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: The CASCADE randomized clinical trial. JAMA. 2018;319: 1103–1112. doi: 10.1001/jama.2018.1818 29509839
11. Rosen S, Maskew M, Larson BA, Brennan AT, Tsikhutsu I, Fox MP, et al. Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): results from an individually randomized trial in South Africa and Kenya Title. PLoS Med. 2019;16: e1002912. doi: 10.1371/journal.pmed.1002912 31525187
12. Brennan AT, Maskew M, Larson BA, Tsikhutsu I, Bii M, Vezi L, et al. Prevalence of tuberculosis symptoms, diagnosis, and treatment among HIV-positive adults not on ART. Abstract 0720, CROI 2020, 2020 Mar 3–6 Boston.
13. TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373: 808–822. doi: 10.1056/NEJMoa1507198 26193126
14. Grant A, Charalambous S, Tlali M, Karat A, Dorman S, Hoffmann C, et al. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV disease: the “TB Fast Track” cluster-randomised trial. Lancet HIV. 2019;3018: 1–11.
15. Rosen S, Maskew M, Brennan AT, Fox MP, Vezi L, Ehrenkranz PD, et al. Improved simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE II): protocol for a randomized evaluation. Trials. 2018;19: 548. doi: 10.1186/s13063-018-2928-5 30305142
16. Ford NP, Geng E, Ellman T, Orrell C, Ehrenkranz PD, Sikazwe I, et al. Emerging priorities for HIV service delivery. PLoS Med. 2020;17:e1003028. doi: 10.1371/journal.pmed.1003028 32059023
17. National Department of Health. Same-day antiretroviral therapy (ART) initiation for HIV positive patients. Pretoria; South African National Department of Health; 2017.
18. Ministry of Health; National AIDS and STI Control Program (NASCOP). Guidelines on the use of antiretroviral drugs for treating and preventing HIV Infection in Kenya 2018 edition. Nairobi: Ministry of Health; 2018 [cited 2020 Jun 9]. Available from: http://cquin.icap.columbia.edu/wp-content/uploads/2017/04/ICAP_CQUIN_Kenya-ARV-Guidelines-2018-Final_20thAug2018.pdf.
19. Ministry of Health. Zambia consolidated guidelines for prevention and treatment of HIV infection 2018. Lusaka: Ministry of Health; 2018 [cited 2020 Jun 9]. Available from: http://www.hivst.org/files1/Final-Zambia-Consolidated-Guidelines_2018-Print.pdf.
20. National Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults. Pretoria, South Africa: National Department of Health; 2015 [cited 2020 Jun 9]. Available from: http://www.health.gov.za/index.php/2014-03-17-09-09-38/policies-and-guidelines/category/230-2015p.
21. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42: 377–381. doi: 10.1016/j.jbi.2008.08.010 18929686
22. Osler M, Hilderbrand K, Hennessey C, Arendse J, Goemaere E, Ford N, et al. A three-tier framework for monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS Soc. 2014;17(1):18908.
23. Brennan AT, Maskew M, Larson BA, Tsikhutsu I, Bii M, Vezi L, et al. Who is seeking antiretroviral treatment for HIV now? Characteristics of patients presenting in Kenya and South Africa in 2017–2018. J Int AIDS Soc. 2019;22:e25358. doi: 10.1002/jia2.25358 31518058
24. Etoori D, Wringe A, Kabudula CW, Renju J, Rice B, Gomez-olive FX, et al. Misreporting of patient outcomes in the South African National HIV Treatment Database: consequences for programme planning, monitoring, and evaluation. Front Public Heal. 2020;8:100.
25. Lilian RR, Rees K, McIntyre JA, Struthers HE, Peters RPH. Same-day antiretroviral therapy initiation for HIV-infected adults in South Africa: Analysis of routine data. PLoS ONE. 2020;15: e0227572. doi: 10.1371/journal.pone.0227572 31935240
26. Fox MP, Rosen S. A new cascade of HIV care for the era of “treat all.” PLoS Med. 2017;14: e1002268. doi: 10.1371/journal.pmed.1002268 28399160
27. Bor J, Fox MP, Rosen S, Venkataramani A, Tanser F, Pillay D, et al. Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa. PLoS Med. 2017;14: e1002463. doi: 10.1371/journal.pmed.1002463 29182641
Článek vyšel v časopise
PLOS Medicine
2020 Číslo 8
- Čokoláda podávaná v malých dávkách neškodí. Vědecky prokázáno!
- MUDr. Václav Šmíd, Ph.D.: Jaterní fibróza a iniciální stadia cirhózy jsou potenciálně vratné stavy
- Esenciální fosfolipidy v podpůrné léčbě jaterní steatózy asociované s metabolickou dysfunkcí
- FDA varuje před selfmonitoringem cukru pomocí chytrých hodinek. Jak je to v Česku?
- Prof. Jan Škrha: Metformin je bezpečný, ale je třeba jej bezpečně užívat a léčbu kontrolovat
Nejčtenější v tomto čísle
- Social distancing to slow the US COVID-19 epidemic: Longitudinal pretest–posttest comparison group study
- Coming together to improve access to medicines: The genesis of the East African Community’s Medicines Regulatory Harmonization initiative
- Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study
- A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial